Moderna, Inc. (MRNA)
| Market Cap | 13.11B |
| Revenue (ttm) | 5.08B |
| Net Income (ttm) | -2.22B |
| Shares Out | 384.82M |
| EPS (ttm) | -5.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,259,731 |
| Open | 33.88 |
| Previous Close | 33.76 |
| Day's Range | 33.60 - 34.75 |
| 52-Week Range | 31.94 - 170.47 |
| Beta | 1.59 |
| Analysts | Hold |
| Price Target | 76.35 (+124.16%) |
| Earnings Date | Feb 20, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $76.35, which is an increase of 124.16% from the latest price.
News
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028. Mer...
Moderna is a 'trade' on Bird Flu vaccine pop, says Mizuho's Jared Holz
Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.
Moderna Gets $590 Million of Federal Funding For Influenza Vaccines
The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the company said
Moderna Announces Updates on Pandemic Influenza Program
CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the developme...
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in human...
CDC upgrades its advisory on bird flu. Will Moderna's stock get a boost?
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or bird.
ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company ...
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook
Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast
Major U.S. equities indexes were mixed to start a new trading week ahead of inflation data that could provide some clarity on the interest-rate outlook for 2025. Earnings reports from the largest U.S....
S&P 500, Nasdaq slip as key tech stocks fall; US Steel shares jump, Moderna stock tanks
US stocks saw a decline on Monday as investors continued to unload key tech shares that have been driving the bull market. The S&P 500 fell by 0.2%, while the Nasdaq Composite dropped 0.8%.
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Shares of pharmaceutical giant Moderna (MRNA) plunged Monday after the company cut its 2025 revenue forecast by $1 billion.
Cramer's Stop Trading: Moderna
CNBC's Jim Cramer explains why he is keeping an eye on shares of Moderna.
Moderna stock takes a 20% hit: here's why
Moderna Inc (NASDAQ: MRNA) tanked as much as 20% in premarket on Monday after lowering its full-year sales guidance by about $1.0 billion. The biotech giant cited headwinds as it revised its outlook t...
TSLA Bull's A.I. Thesis, LULU Ups Guidance & MRNA Plunges
Morgan Stanley raised its price target on Tesla (TSLA) with optimism behind the company's A.I. and autonomous driving expectations.
Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
Moderna Inc. MRNA stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing ...
Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of whi...
Moderna's stock tumbles to post-COVID lows after revenue outlook disappoints
Moderna's stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
Moderna 2025 Revenue Guidance Below Estimates
The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street expectations of $2.9 billion.
Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.
The company said Monday that it expects 2025 revenue of between $1.5 billion and $2.5 billion.
Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines.
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / January 13, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2025 with a focus on a p...
mRNA Cancer Vaccines Clinical Trials Ongoing Research Development Insight
First Commercial mRNA Vaccine Approval Expected By 2029 Says Kuick Research First Commercial mRNA Vaccine Approval Expected By 2029 Says Kuick Research
Stock Market Today: Stocks End Mixed After FOMC Minutes
The minutes from the December Fed meeting signaled central bankers' uncertainty over potential Trump administration policies.